Abstract 812: Identification of novel anticancer drugs as substrates of organic anion transporting polypeptide 1B3 using a cell viability assay

2012 ◽  
Author(s):  
Amanda L. Obaidat-Hays ◽  
Bruno Hagenbuch
Keyword(s):  
Cell Viability ◽  
Anticancer Drugs ◽  
Organic Anion ◽  
Cell Viability Assay ◽  
Organic Anion Transporting Polypeptide ◽  
Viability Assay ◽  
A Cell

A Cell Viability Assay Based on Monitoring Respiration by Optical Oxygen Sensing

2000 ◽  
Vol 278 (2) ◽  
pp. 221-227 ◽  
Author(s):  
Tomás C. O'Riordan ◽  
Deirdre Buckley ◽  
Vladimir Ogurtsov ◽  
Rosemary O'Connor ◽  
Dmitri B. Papkovsky
Keyword(s):  
Cell Viability ◽  
Oxygen Sensing ◽  
Cell Viability Assay ◽  
Viability Assay ◽  
A Cell

scholarly journals Nano-engineered skin mesenchymal stem cells: potential vehicles for tumour-targeted quantum-dot delivery

2017 ◽  
Vol 8 ◽  
pp. 1218-1230 ◽  
Author(s):  
Liga Saulite ◽  
Dominyka Dapkute ◽  
Karlis Pleiko ◽  
Ineta Popena ◽  
Simona Steponkiene ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cell Viability ◽  
Cell Viability Assay ◽  
Ki67 Expression ◽  
Lineage Differentiation ◽  
Viability Assay ◽  
Late Endosomes ◽  
Early Endosomes ◽  
A Cell

Nanotechnology-based drug design offers new possibilities for the use of nanoparticles in imaging and targeted therapy of tumours. Due to their tumour-homing ability, nano-engineered mesenchymal stem cells (MSCs) could be utilized as vectors to deliver diagnostic and therapeutic nanoparticles into a tumour. In the present study, uptake and functional effects of carboxyl-coated quantum dots QD655 were studied in human skin MSCs. The effect of QD on MSCs was examined using a cell viability assay, Ki67 expression analysis, and tri-lineage differentiation assay. The optimal conditions for QD uptake in MSCs were determined using flow cytometry. The QD uptake route in MSCs was examined via fluorescence imaging using endocytosis inhibitors for the micropinocytosis, phagocytosis, lipid-raft, clathrin- and caveolin-dependent endocytosis pathways. These data showed that QDs were efficiently accumulated in the cytoplasm of MSCs after incubation for 6 h. The main uptake route of QDs in skin MSCs was clathrin-mediated endocytosis. QDs were mainly localized in early endosomes after 6 h as well as in late endosomes and lysosomes after 24 h. QDs in concentrations ranging from 0.5 to 64 nM had no effect on cell viability and proliferation. The expression of MSC markers, CD73 and CD90, and hematopoietic markers, CD34 and CD45, as well as the ability to differentiate into adipocytes, chondrocytes, and osteocytes, were not altered in the presence of QDs. We observed a decrease in the QD signal from labelled MSCs over time that could partly reflect QD excretion. Altogether, these data suggest that QD-labelled MSCs could be used for targeted drug delivery studies.

Evaluation of the Influence of Ferrite Magnetic Nanoparticle for Cancer Cell

2021 ◽  
Vol 323 ◽  
pp. 146-151
Author(s):  
Khishigdemberel Ikhbayar ◽  
Nomin Myagmar ◽  
Gantulga Davaakhuu ◽  
Uyanga Enkhnaran ◽  
Enkhmend Bekhbaatar ◽  
...  
Keyword(s):  
Cell Viability ◽  
Colony Formation ◽  
Magnetic Nanoparticle ◽  
In Vitro Cytotoxicity ◽  
Colony Formation Assay ◽  
Cell Viability Assay ◽  
Cytotoxic Effects ◽  
Viability Assay ◽  
A Cell

Magnetic nanoparticles for thermotherapy must be biocompatible and possess high thermal efficiency as heating elements. The biocompatibility of Mg 0.8 Ni 0.2 Fe 2 O 4 nanoparticles was studied using a cytotoxicity colony formation assay and a cell viability assay. HeLa cells exhibited cytotoxic effects when exposed to three different concentrations of 150 μg /ml, 100 μg /ml, and 50 μg /ml nanoparticles. Therefor e, c oncentrations of 50 μg /ml showed the lowest cytotoxic activity and the lowest toxicity to living cells. In vitro cytotoxicity of samples was then investigated by two methods, colony formation assay and cell viability assay. The Hela inhibited cell growth as 16.8% during heating by magnetic field generators.

Development of a cell viability assay to assess drug metabolite structure–toxicity relationships

2016 ◽  
Vol 26 (16) ◽  
pp. 4003-4006 ◽  
Author(s):  
Payal Rana ◽  
Yvonne Will ◽  
Sashi Nadanaciva ◽  
Lyn H. Jones
Keyword(s):  
Cell Viability ◽  
Cell Viability Assay ◽  
Viability Assay ◽  
Drug Metabolite ◽  
A Cell

scholarly journals A cell viability assay to determine the cytotoxic effects of water contaminated by microbes

2013 ◽  
Vol 109 (7/8) ◽  
pp. 1-4 ◽  
Author(s):  
Suranie Prinsloo ◽  
Rialet Pieters ◽  
Carlos C. Bezuidenhout
Keyword(s):  
Cell Viability ◽  
Cell Viability Assay ◽  
Cytotoxic Effects ◽  
Viability Assay ◽  
A Cell

Synthesis and Antitumor Activity of Some N2-(Thien-3-yl)amidrazones

2014 ◽  
Vol 69 (7) ◽  
pp. 811-816 ◽  
Author(s):  
Mohammed M. Abadleh ◽  
Mustafa M. El-Abadelah ◽  
Salim S. Sabri ◽  
Hanan H. Mohammed ◽  
Malek A. Zihlif ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Antitumor Activity ◽  
Cell Viability ◽  
Cell Lines ◽  
K562 Cell ◽  
Cyclic Amine ◽  
Cell Viability Assay ◽  
Viability Assay ◽  
A Cell ◽  
Mcf 7

6aA set of new N2-(thien-3-yl)amidrazones (-h) incorporating N-piperazines and related congeners has been synthesized by reacting the hydrazonoyl chloride 4(derived from 3-aminothiophene- 2-carboxylate) with the appropriate sec-cyclic amine. The antitumor activity of these compounds was evaluated on breast cancer (MCF-7) and leukemic (K562) cell lines by a cell viability assay utilizing the tetrazolium dye (MTT). The amidrazone 6d encompassing the N-piperazine moiety, was the most active against MCF-7 and K562 with IC50 of 7.28 and 9:91 μM, respectively.

Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 338-338
Author(s):  
Mark Ricigliano ◽  
William H. Isacoff ◽  
Allyson J. Ocean ◽  
Brandon Cooper ◽  
Mary Welkie ◽  
...  
Keyword(s):  
Cell Viability ◽  
Treatment Options ◽  
Standard Of Care ◽  
Response To Treatment ◽  
Patient Treatment ◽  
P Value ◽  
Line Treatment ◽  
Cell Viability Assay ◽  
Viability Assay ◽  
A Cell

338 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) includes FOLFIRINOX or gemcitabine with nab-paclitaxel used in either the front-line or 2nd line treatment setting. There is no consensus for 3rd line treatment for this cohort of poor prognosis patients with clinical trials being the only viable option. We evaluated a cell viability assay using cultures of circulating tumor and invasive cells (CTICs) to identify effective 3rdline PDAC treatment options. Methods: CTICs were isolated from peripheral blood samples of 17 PDAC patients who previously had received one of the two standard of care regimens using an immunomagnetic separation for EPCAM epitope Ber-EP4 and cultured in enriched DMEM-F12 medium. After 14 days, seven chemotherapeutics (gemcitabine (G), oxaliplatin (O), fluorouracil (F), irinotecan (I), mitomycin C (M), cisplatin (C) and paclitaxel (P)) were added to the cultures and response to treatment was measured 48 hr. after treatment by immunofluorescence using a live-cell resazurin assay. Response to treatment was determined by a reduction of fluorescence in the treated cultures compared to control and the mean florescence (Fm) was calculated for each chemotherapeutic. A one-sample t-test was used to measure the variance between Fm control and treated samples. (p-value <0.005). Sensitivity to treatment was determined using linear regression based on Fm values and the sensitivity of each chemotherapeutic was interpolated from a standard curve (range 1.0-5.0, sensitive <2, intermediate 2-3, resistant >3). Results: m (Fm=1.6) demonstrated the most effective treatment option with marked resistance to treatment for G, I, P and O. (Fm=3.4, 3.7, 3.4 and 3.7). Intermediate response was observed for F and C (Fm=2.8 and 2.8). Patient treatment response to m will be described. Conclusions: CTICs can be routinely isolated and cultured for cell viability assays. m based regimens with C and F should be considered for 3rd line PDAC patients.

Sign in / Sign up

Export Citation Format

Share Document